In addition to consolidations at its New Jersey R&D facility, Roche (RHHBY.PK +1.9%) says...

In addition to consolidations at its New Jersey R&D facility, Roche (RHHBY.PK+1.9%) says Jean-Jacques Garaud, its head of Pharmaceutical Research and Early Development, is leaving the company effective June 30. Mike Burgess, currently Global Head Oncology and Large Molecule Research, will become acting head until a replacement its found, reporting directly to CEO Severin Schwan.